APA (7th ed.) Citation

TS, Z., F, E., J, G., M, M., M, S., C, K., & E, S. (2025). Soluble Urokinase Plasminogen Activator Receptor (suPAR) Plasma Concentration Is Reduced Using Minimized Extracorporeal Circulation: Results of a Secondary Analysis of a Prospective Observational Study. Journal of clinical medicine, 14(14), . https://doi.org/10.3390/jcm14145020

Chicago Style (17th ed.) Citation

TS, Zajonz, Edinger F, Götze J, Markmann M, Sander M, Koch C, and Schneck E. "Soluble Urokinase Plasminogen Activator Receptor (suPAR) Plasma Concentration Is Reduced Using Minimized Extracorporeal Circulation: Results of a Secondary Analysis of a Prospective Observational Study." Journal of Clinical Medicine 14, no. 14 (2025). https://doi.org/10.3390/jcm14145020.

MLA (9th ed.) Citation

TS, Zajonz, et al. "Soluble Urokinase Plasminogen Activator Receptor (suPAR) Plasma Concentration Is Reduced Using Minimized Extracorporeal Circulation: Results of a Secondary Analysis of a Prospective Observational Study." Journal of Clinical Medicine, vol. 14, no. 14, 2025, https://doi.org/10.3390/jcm14145020.